What is the typical starting dose of insulin glargine (insulin glargine) for a patient with type 1 diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Insulin Glargine Dosing in Type 1 Diabetes

Starting Dose

For metabolically stable patients with type 1 diabetes, start with a total daily insulin dose of 0.5 units/kg/day, giving approximately 50% (or one-third to one-half) as insulin glargine once daily and 50% as rapid-acting prandial insulin divided among meals. 1, 2

Calculating the Initial Dose

  • Total daily insulin requirement: 0.4-1.0 units/kg/day, with 0.5 units/kg/day being typical for metabolically stable patients 1
  • Basal insulin (glargine) component: 40-50% of total daily dose (approximately one-third per FDA labeling) 1, 2
  • Prandial insulin component: 50-60% of total daily dose, divided among three meals 1

Example Calculation

For a 70 kg patient with type 1 diabetes:

  • Total daily dose: 0.5 units/kg/day × 70 kg = 35 units/day
  • Insulin glargine: 17-18 units once daily
  • Rapid-acting insulin: 17-18 units total, divided as approximately 6 units before each meal

Special Populations Requiring Dose Adjustments

  • Honeymoon phase or residual beta-cell function: May require lower doses of 0.2-0.6 units/kg/day 1
  • Puberty, pregnancy, or acute illness: May require higher doses, potentially exceeding 1.0 units/kg/day 1
  • Immediately following ketoacidosis: Require higher weight-based dosing 1

Administration Guidelines

  • Timing: Administer subcutaneously once daily at the same time each day—morning, evening, or bedtime—whichever is most convenient 1, 2
  • Injection sites: Abdomen, thigh, deltoid, or buttock 1, 2
  • Site rotation: Rotate injection sites within the same region to prevent lipodystrophy and localized cutaneous amyloidosis 1, 2
  • Needle size: Use 4-mm pen needles to minimize risk of intramuscular injection 1

Titration Protocol

Adjust insulin glargine by 2-4 units every 3 days based on fasting blood glucose patterns until reaching a target of 80-130 mg/dL. 1

Specific Titration Algorithm

  • If fasting glucose is 140-179 mg/dL: Increase insulin glargine by 2 units every 3 days 1
  • If fasting glucose is ≥180 mg/dL: Increase insulin glargine by 4 units every 3 days 1
  • If hypoglycemia occurs: Reduce the dose by 10-20% immediately 1

Critical Threshold: When to Stop Escalating Basal Insulin

Stop escalating insulin glargine when the dose exceeds 0.5 units/kg/day and approaches 1.0 units/kg/day; instead, intensify prandial insulin coverage rather than continuing to increase basal insulin. 1

Signs of Overbasalization

  • Basal dose >0.5 units/kg/day 1
  • Bedtime-to-morning glucose differential ≥50 mg/dL 1
  • Hypoglycemia episodes 1
  • High glucose variability 1

Special Considerations for Renal Impairment

  • CKD Stage 5: Reduce total daily insulin dose by 35-40% in type 1 diabetes 1
  • eGFR <45 mL/min/1.73 m²: Titrate conservatively and monitor more closely for hypoglycemia 1

Hypoglycemia Management

  • Treatment threshold: Treat any glucose <70 mg/dL immediately with 15 grams of fast-acting carbohydrate 1
  • Recheck: Recheck in 15 minutes and repeat if needed 1
  • Prevention: All patients must carry at least 15g carbohydrate at all times 1
  • Reversing hypoglycemia unawareness: Scrupulous avoidance of hypoglycemia for 2-3 weeks can reverse hypoglycemia unawareness 1

Important Contraindications and Warnings

  • Do not mix or dilute: Insulin glargine must not be diluted or mixed with any other insulin or solution due to its low pH 1, 2
  • Do not administer intravenously: Only subcutaneous administration 2
  • Do not use in insulin pumps: Not approved for continuous subcutaneous insulin infusion 2
  • Avoid lipodystrophy areas: Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis, as this causes erratic absorption 1, 2

Switching from NPH Insulin

  • From once-daily NPH: Use the same dose of insulin glargine 2
  • From twice-daily NPH: Start insulin glargine at 80% of the total NPH dosage 2

References

Guideline

Insulin Glargine Dosing in Type 1 Diabetes

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.